Viewing Study NCT06926868

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:47 PM
Ignite Modification Date: 2025-12-28 @ 12:52 AM
Study NCT ID: NCT06926868
Status: RECRUITING
Last Update Posted: 2025-12-15
First Post: 2025-04-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Sponsor: Bristol-Myers Squibb
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None triple-negative breast cancer View
None antibody-drug conjugate View